Endocrine Abstracts

Background: Investigating the origin of ACTH determine disparate treatment and prognosis in ACTH-dependent Cushing’s Syndrome. We want to detect the value of combination of HDDST and DDAVP stimulation test for identifying Cushing’s disease (CD) and Ectopic ACTH-dependent Cushing’s Syndrome (EAS).Methods: We retrospectively recorded 102 ACTH-dependent Cushing’s Syndrome (87 CD and 15 EAS) in West China Hospital from January 1, 2010...

Summary: Objective: To evaluate the expression level and binding affinity of glucocorticoid receptors (GRs)in patients with endogenous Cushing’s syndrome(CS) and to determine whether there is partial glucocorticoid resistance.Methods: Fifty-eight patients with CS and forty-one age- and sex-matched healthy volunteers were studied. The expression level and binding affinity of GRs in peripheral blood mononuclear cells (PBMLs) were examined by flow cyt...

Objective: To examine the relationship between C-peptide levels and endogenous insulin secretion and to understand the effects of elevated C-peptide after dosing on evaluating study insulin and its analogs’ PK/PD values in euglycemic clamps.Method: The study included 33 healthy male volunteers who underwent an 8-h euglycemic clamp with a subcutaneous injection of insulin aspart (0.2 U/kg). Blood glucose (BG), C-peptide, human insulin, and insu...

Background: Cushing’s disease (CD) is associated with hypercortisolism-induced cardiovascular morbidity and mortality and impaired patient quality of life (QoL). We report long-term effects of osilodrostat (potent 11β-hydroxylase inhibitor) on cardiovascular/metabolic-related risk factors, physical features of hypercortisolism and QoL in CD patients following the core and extension phases of the LINC 4 study (NCT02697734).Methods: LINC 4 compri...

Background: Pasireotide has proven efficacy in acromegaly and CD, although pasireotide-associated hyperglycaemia occurs in some patients. This Phase IV, randomized, open-label study investigated optimal management of pasireotide-associated hyperglycaemia uncontrolled by metformin/oral antidiabetic therapy (OAD) [NCT02060383].Methods: Adults with acromegaly or CD were enrolled and treated with long-acting pasireotide 40 mg/28 days or subcutaneous pasireot...

Introduction: Osilodrostat (oral 11β-hydroxylase inhibitor) demonstrated rapid, sustained cortisol normalisation in Phase III studies (LINC 3, NCT02180217; LINC 4, NCT02697734) in patients with Cushing’s disease (CD). Relative osilodrostat bioavailability is ~20% higher in Asian patients than other ethnicities; body weight is not a major determinant of this difference. This analysis of LINC 3 and LINC 4 evaluated osilodrostat efficacy and safety in Asian and non-Asia...